Lineage Cell Therapeutics

All of us at $LCTX and CCN wish to express our gratitude to those who inspire us as #WeWorktoRestore - function, dignity, strength, clarity, independence, and hope. @CEO_Culley #CellTherapy #ReplaceAndRestore #Careers

We appreciate Dr. Joe Pantginis of @HCWCO for hosting a fireside chat with $LCTX ‘s @CEO_Culley as part of @HCWCO 4th Annual BioConnect Investor Conference at @NasdaqExchange. Replay available here: bit.ly/3m7EWIp #CellTherapy #InvestorRelations #ReplaceandRestore

We’d like to thank European Pharmaceutical Review for featuring $LCTX ’s @CEO_Culley in its 2026 Cell and Gene Therapy report, where he discusses scalable, off-the-shelf cell therapies and the role of manufacturing, scale, and control in development. Read the full report: bit.ly/4eMqL8i #CellTherapy #RegenerativeMedicine #CellManufacturing

$LCTX reported first quarter 2026 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update. Learn more: bit.ly/4nn1p2W #ReplaceAndRestore

$LCTX will report Q1 2026 financial and operating results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to provide a business update. For more: investor.lineagecell.com/news-releases/… #ReplaceAndRestore

OpRegen® (RG6501) 3-year Phase 1/2a clinical study results in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were presented at @FightBlindness’ Retinal Therapeutics Innovation Summit 2026 on behalf of @Roche and @Genentech. Imaging evidence of structural benefit and greater gains in visual acuity seen in study eyes in Cohort 4 patients (less advanced GA) at month 12, continuing through month 36. Differences as compared with fellow eyes increased over time, suggesting possible modification of the course of disease. For more: bit.ly/497P4K4 $LCTX #CellTherapy #GeographicAtrophy #AMD #Retina

$LCTX @CEO_Culley joined @irat1onal on @ProgressPotent1 to discuss Lineage’s approach to allogeneic cell therapy, our proprietary AlloSCOPE™ manufacturing platform, and off-the-shelf cell therapies. youtu.be/fwBDF8oVHJo #CellTherapy #RegenerativeMedicine #CellManufacturing #ReplaceAndRestore

Please join us in welcoming Priyantha Herath, M.D., Ph.D., to $LCTX as Senior Vice President, Head of Clinical. A board-certified neurologist, Dr. Herath brings translational, regulatory and Phase 3 clinical development experience, with prior roles at @argenxglobal, @Alnylam, @VoyagerTx, and @JazzPharma. He received his M.D. with honors from University of Peradeniya and his Ph.D. in Neuroscience from Karolinska Institutet. For more: bit.ly/4t8nWm3 #ReplaceandRestore #BiotechLeadership #ClinicalDevelopment #LeadershipTeam

$LCTX establishes a Scientific Advisory Board, with Joachim Fruebis, Ph.D., as its founding member. He brings deep R&D and leadership experience across multiple therapeutic areas, most recently serving as Corporate VP, Cell Therapy R&D at @novonordisk. He received his Ph.D. and M.S. in Biology from the University Kaiserslautern, Germany, with research conducted at @UCSanDiego. For more: bit.ly/4t8nWm3 #Biotech #CellTherapy #Leadership #ReplaceandRestore

$LCTX thanks @SDJournal for highlighting our expansion into corneal endothelial disease with COR1, targeting a growing global population affected by FECD. Read the full article: sdbj.com/life-sciences/… #CellTherapy #Ophthalmology #Biotech #RegenerativeMedicine

$LCTX @CEO_Culley shares his perspective in @BioSpace on the growing complexity of drug discovery, highlighting the role of scalable platforms and aligning innovation with real-world clinical needs. bit.ly/47AsIQS #DrugDiscovery #CellTherapy #Biotech #Innovation #RegenerativeMedicine

$LCTX has launched COR1, a corneal endothelial cell therapy program in preclinical development for corneal endothelial disease. Built on its AlloSCOPE™ platform, COR1 aims to deliver off-the-shelf CEnCs for Fuchs Endothelial Corneal Dystrophy (FECD) and Bullous Keratopathy. For more: bit.ly/4rUBlwK #CornealEndothelialDisease #Ophthalmology #FECD #CellTherapy

$LCTX

$LCTX reported fourth quarter and full year 2025 financial results and will host a conference call at 4:30 pm ET / 1:30 pm PT today to provide a business update. Learn more: bit.ly/4dazDDA #ReplaceAndRestore

$LCTX will report 4Q and full year 2025 financial results on Thursday, March 5, 2026, and host a conference call at 4:30 pm ET / 1:30 pm PT to provide a business update. Learn more: bit.ly/4ufcw19 #ReplaceAndRestore

$LCTX has activated a second DOSED clinical study site for #OPC1, its allogeneic cell transplant therapy candidate for spinal cord injury, at @RanchoResearchI, in conjunction with their affiliated hospital, @RanchoRehab, where Charles Liu, M.D., Ph.D., will serve as Principal Investigator. For more about Rancho Research Institute, please visit: bit.ly/4qXSrKo For more about Rancho Los Amigos National Rehabilitation Center, please visit: bit.ly/4gmHBsI For more about DOSED, please visit: bit.ly/45QJ0Ei #ReplaceandRestore #ClinicalTrials #SCI #SpinalCordInjury

.@CEO_Culley of $LCTX spoke with @pharmaphorum reporter @JonahComstock about why allogeneic, off-the-shelf cell therapy still has a path beyond oncology, plus long-term tolerability data and what Lineage plans to share about its cell programs in 2026. For more: bit.ly/4tgBFrq #CellTherapy #RegenerativeMedicine #Biotech

$LCTX #OpRegen #dryAMD

Rami Skaliter, CEO of Cell Cure Neurosciences, a $LCTX subsidiary, is presenting at @HansonWade’s 4th Annual Ophthalmic Drug Delivery Summit in San Francisco, hosting a workshop session on overcoming clinical applicability challenges in cell therapy for vision and beyond. For more about the conference: bit.ly/3M6vk1a #Ophthalmology #DrugDelivery #CellTherapy

.@CEO_Culley of $LCTX joined @Fraiser_K, the host of The Top Line podcast from @FiercePharma, for a conversation about investor sentiment and why manufacturing planning needs to start earlier than most teams think. Listen here: bit.ly/4qk1UeT #Biotech #CellTherapy #Manufacturing #HealthcareInnovation

.@CEO_Culley and the $LCTX business development team are in San Francisco for JPMorgan Healthcare Conference Week, where we’re looking forward to key investor, partnering, and biotech discussions. #ReplaceAndRestore #RegenerativeMedicine #JPM2026